EX1 (ASX) Ann: Appointment of Company Secretary

Exopharm Strengthens Executive Leadership Team

* Mr David Oxley appointed as President -International
* Dr Johannes K Mühl appointed as Senior VicePresident - Finance

4 October 2021, Melbourne, Australia: Exosome medicinescompany, Exopharm Limited (ASX: EX1) has made two senior appointments insupport of its international strategy.

Mr David Oxley appointed as President - International

David Oxley’s appointment extends the company’s reach toa growing network of global and regional strategic partners and internationalcapital markets.

David brings more than twenty years professionalexperience to Exopharm, including complex, multi-product, cross-borderlicensing expertise, product candidate development and approval,commercialization, and capital markets. Within the biotech sector, David’s experience includes ten years ofexecutive leadership responsibility within the regenerative medicine sector inChina, Australia, and the US. Beyond thebiotech sector, David has served on the board of directors of a private,antibody-based bioscience company along with a not-for-profit foundationfocused on infectious diseases in Africa.

Prior to his tenure within the biotech sector, Davidserved a combined eighteen years in executive leadership roles in the lifesciences arena, including head of global sales and marketing and head of globalgovernment relations for medical devices companies, health-care capital marketsmanagement for a leading U.S. bank, policy advocacy before the U.S. Food andDrug Administration in addition to health-care legislative work for a Member ofthe United States Congress.

Mr. Oxley holds a bachelor’s degree from Portland StateUniversity and masters work from Johns Hopkins University.

Dr Johannes K Mühl appointed as Senior Vice President -Finance

Based in Zurich, Switzerland, Dr Johannes Mühl has joinedExopharm as Senior Vice President Finance. Johannes has a vast network in thelife-science industry and is also a successful private investor in the biotechsector.

At Exopharm, Johannes is building the profile of the Companyin the investment community and helping to shape Exopharm’s pipeline productsand associated strategy and finance plan.

Johannes brings with him a wealth of transferable skills– analytical precision, deep understanding of Finance and Accounting acrosscontinents, deal making and thorough knowledge of the gene therapeutics anddiagnostics market.

Previously, Johannes was International Head of Financeand Business Insights at Myriad Genetics where he co-led the organisationthrough a successful transformation with growth of top and bottom line. He hasover 15 years of life-science industry finance experience with roles in Pfizerand Zimmer Biomet.

Johannes has a PhD from Edinburgh Napier University andis a Fellow of the Institute of Public Accountants (FIPA) Australia. Johannesalso has a Diploma of International Business Administration from FurtwangenUniversity and is currently studying towards a Master of Public Health at theUniversity of Zurich.

David and Johannes report to Founder & CEO, Dr IanDixon.

“We welcome David and Johannes to the organization as wetransition into a global exosome medicines company and engage internationalinvestors, payers, strategic partners and other stakeholders,” said Dr Dixon.

Company and Media Enquiries:
Dr Ian Dixon, MBA
Founder and Managing Director
P: +61 (0)3 9111 0026
[email protected]<mailto:[email protected]>